By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ligand Pharmaceuticals Inc. 

10275 Science Center Drive

San Diego  California  92121  U.S.A.
Phone: 858-550-7500 Fax: 858-550-7506


SEARCH JOBS




Collaborations

GlaxoSmithKline  - In 1995, we entered into a research and development collaboration with SmithKline Beecham (now GlaxoSmithKline) to use our proprietary expertise to discover and characterize small-molecule, orally bioavailable drugs to control hematopoiesis (the formation and development of blood cells) for the treatment of a variety of blood cell deficiencies. Eltrombopag and a back up compound, SB-559448, resulted from this collaboration. These compounds are orally active, non-peptide, small molecule thrombopoietin (TPO) mimetics for the treatment of thrombocytopenia (low platelet counts). Eltrombopag is in Phase III clinical trials for immune thrombocytopenic purpura (ITP). GlaxoSmithKline plans to file an NDA for the ITP indication in late 2007/early 2008. A Phase III clinical trial in patients with hepatitis C is planned in 2H07. In addition, Phase I/II studies are ongoing in patients with chemotherapy-induced thrombocytopenia. The backup compound, SB-559448, is in Phase I clinical trials.

Pfizer  - We collaborated with Pfizer to develop therapies for osteoporosis. The collaboration produced lasofoxifene (Oporia™), that Pfizer has advanced through late-stage clinical development. Lasofoxifene (Oporia) is a SERM that is being developed for the treatment and prevention of post-menopausal osteoporosis and vaginal atrophy. Pfizer plans to re-file the lasofoxifene NDA for the prevention of osteoporosis in late 2007.

TAP Pharmaceutical Products Inc.  - In June 2001, we entered into a joint research and development alliance with TAP Pharmaceutical Products discovery and develop selective androgen receptor modulators (SARMs) for the treatment of osteoporosis, frailty, wasting disorders (such as cancer cachexia), and male hypogonadism. LGD-2941 is a product of that collaboration. LGD-2941 is in Phase I clinical trials.

Wyeth  - In 1994, we entered into a research and development collaboration with Wyeth-Ayerst Laboratories (now Wyeth) to discover and develop drugs that interact with estrogen and progesterone receptors for use in hormone therapy, anti-cancer therapy, gynecological diseases and central nervous system disorders associated with menopause and fertility control. Bazedoxifene, a selective estrogen receptor modulator (SERM), is the product of this collaboration.

Bazedoxifene (Viviant) is a synthetic drug that was designed to increase bone density while protecting breast and uterine tissue. Wyeth is developing bazedoxifene (Viviant) for the treatment and prevention of post-menopausal osteoporosis. FDA action on the Viviant NDA for the prevention of osteoporosis is expected in late 2007. Wyeth plans to submitted a second NDA for Viviant for the treatment of osteoporosis in 3Q07.

Wyeth is developing bazedoxifene in combination with Premarin® (Aprela) as a progesterone-free treatment for menopausal symptoms including osteoporosis and hot flush. Wyeth plans to file an NDA for Aprela in late 2007.





Company News
Ligand Pharmaceuticals Inc. (LGND) To Host Analyst Day On November 18th In New York City 10/16/2014 8:14:07 AM
Ligand Pharmaceuticals Inc. (LGND) Reports Third Quarter Revenues And Expected Diluted EPS 10/8/2014 7:54:01 AM
Ligand Pharmaceuticals Inc. (LGND) Earns Milestone Payment Triggered By EU Approval Of Merck & Co. (MRK)’s Captisol-Enabled NOXAFIL® (posaconazole) Concentrate For Solution For Infusion 9/26/2014 8:18:32 AM
Ligand Pharmaceuticals Inc. (LGND) Licenses Captisol-Enabled™ Lamotrigine To CURx Pharmaceuticals 9/9/2014 10:44:42 AM
Lemelson Capital Comments On Large Institutional Selling In Shares Of Ligand Pharmaceuticals Inc. (LGND) Amidst Company's Insolvency And Mounting Going Concern Risk 8/25/2014 1:41:38 PM
Ligand Pharmaceuticals Inc. (LGND) Signs Multi-Program Captisol® License Agreement With Avion Pharmaceuticals 8/14/2014 8:02:26 AM
Ligand Pharmaceuticals Inc. (LGND) Prices Offering Of $225 Million Of Convertible Senior Notes 8/13/2014 8:01:46 AM
Ligand Pharmaceuticals Inc. (LGND) Announces Proposed Offering Of $225 Million Of Convertible Senior Notes And Announces $200 Million Share Repurchase Program 8/12/2014 8:54:44 AM
Ligand Pharmaceuticals Inc. (LGND) Reports Second Quarter 2014 Financial Results 8/4/2014 10:06:06 AM
Ligand Pharmaceuticals Inc. (LGND) Partner GlaxoSmithKline (GSK) Announces Record Quarterly Promacta™/Revolade™ Revenue Of $92 Million 7/24/2014 7:27:24 AM
12345678910...
//-->